20 January 2025
Clifford Chance advises Sanofi on acquisition of exclusive Greater China rights to develop and commercialise aficamten
Advising firms
Deal team
4 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Yang Yi Lead | Clifford Chance | Partner | Not stated | Not stated |
| Matthew Warner Lead | Clifford Chance | Partner | Not stated | New York |
| Daryl Fairbairn | Clifford Chance | Counsel | Not stated | New York |
| Bao Fang | Clifford Chance | Counsel | Not stated | Shanghai |
Stated terms
- Stated value
- Not stated
- What the figure measures
- Not stated
- Client
- SanofiBuy-side
- Counterparties
- Corxel Pharmaceuticals (Sell-side)